by Neoteryx | 3 min read
The human immune system is conditioned to attack anything it identifies as "foreign." When a patient receives an organ transplant, their immune system typically identifies the new organ as foreign, …
Read Storyby Neoteryx | 2 min read
Immunosuppressive drugs are mandatory when a patient is going through procedures like organ or tissue transplantation, chemotherapy, or suffering from autoimmune diseases. This is because ISP drugs have a narrow …
Read Storyby Neoteryx | 2 min read
Expert interpretation of drug concentration is critical to understanding pharmacokinetics and realizing full its clinical benefits. Clinicians achieve this by monitoring drug pharmacodynamics routinely and measuring physiological indices of therapeutic responses directly. However, …
Read Storyby Neoteryx | 2 min read
Immunosuppression prevents and treats acute rejection and graft damage during kidney transplantation. The development immunosuppressive agents such as tacrolimus, cyclosporine, and mycophenolate minimized the rejection rate and improved short-term graft …
Read Storyby Neoteryx | 2 min read
Over the past five decades, the medical community has witnessed considerable advancements in organ transplants. Patients receive organs, and through immunosuppressive drugs, their bodies can accept the organ. Therefore, the …
Read Storyby Neoteryx | 1 min read
When Fasha Mahjoor launched Neoteryx, he planned to change the way dried capillary blood is collected, to become the most significant blood microsampling innovator in the modern marketplace. In that, …
Read StoryLearn about insights, research, case studies, and tutorials on integrating remote specimen collection, microsampling, and more!
© Neoteryx 2021 | Privacy Policy | Sitemap
421 Amapola Ave
Torrance, CA 90501
This site is protected by reCAPTCHA and the Google Privacy
Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of biological fluids. They are CE-IVD self-certified in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada, Thailand, and Ukraine. In the United States, Mitra devices are for Research Use Only (RUO). In some countries, Mitra devices may be used in clinical diagnostic laboratory systems after the laboratory has validated their complete system in compliance with relevant rules and regulations. Mitra is a registered trademark of Neoteryx, LLC.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use. hemaPEN® is a registered trademark owned by Trajan Scientific Australia Pty Ltd.
Copyright © 2022 Neoteryx, LLC, Part of the Trajan Family. All rights reserved.